The effect of choice of platinum on survival and factors affecting survival in metastatic small cell lung cancer: A Single Center Experience
INTRODUCTION: In this retrospective study, we aimed to analyze the effect of choice of platinum chemotherapy (carboplatin vs. cisplatin) on survival in patients with small cell lung cancer(SCLC) and to identify the factors affecting survival. METHODS: A total of 87 metastatic SCLC patients with avai...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Van Yuzuncu Yil University, School of Medicine
2021-01-01
|
| Series: | Van Tıp Dergisi |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=vtd&un=VTD-46244 |
| _version_ | 1827608549830688768 |
|---|---|
| author | Ayşegül Sakin mehmet naci aldemir murat alay |
| author_facet | Ayşegül Sakin mehmet naci aldemir murat alay |
| author_sort | Ayşegül Sakin |
| collection | DOAJ |
| description | INTRODUCTION: In this retrospective study, we aimed to analyze the effect of choice of platinum chemotherapy (carboplatin vs. cisplatin) on survival in patients with small cell lung cancer(SCLC) and to identify the factors affecting survival. METHODS: A total of 87 metastatic SCLC patients with available data, who were equal to or greater than 18 years and were treated with platinum-based chemotherapy at first-line setting, were included. Patients were grouped according to type of platinum treatment as ‘cisplatin + etoposide(PE)' or ‘carboplatin + etoposide(CE)'. RESULTS: Of the 87 patients included in the study, 16 (%18,4) were female. The median age was 58 years. The numbers of patients treated with PE and CE were 65 and 22, respectively. The median progression-free survivals of patients treated with PE vs. CE were 6 months and 5 months, respectively (p=0.171), with corresponding overall survival (OS) durations of 9 months and 8 months (p=0.173). Performance status, administering thoracic radiotherapy and response to first-line chemotherapy were found to be the independent factors affecting OS. DISCUSSION AND CONCLUSION: In our study, first-line treatment with CE vs. PE did not affect survival in the patients with metastatic SCLC. However, the survival of patients with poor performance status was observed to be lower than those with better performance status. In addition, administering thoracic radiotherapy and a better response to first-line chemotherapy improved survival. |
| first_indexed | 2024-03-09T07:15:54Z |
| format | Article |
| id | doaj.art-bee5cbbcb2eb4641a853b7470874d956 |
| institution | Directory Open Access Journal |
| issn | 2587-0351 |
| language | English |
| last_indexed | 2024-03-09T07:15:54Z |
| publishDate | 2021-01-01 |
| publisher | Van Yuzuncu Yil University, School of Medicine |
| record_format | Article |
| series | Van Tıp Dergisi |
| spelling | doaj.art-bee5cbbcb2eb4641a853b7470874d9562023-12-03T08:39:30ZengVan Yuzuncu Yil University, School of MedicineVan Tıp Dergisi2587-03512021-01-01281849010.5505/vtd.2021.46244VTD-46244The effect of choice of platinum on survival and factors affecting survival in metastatic small cell lung cancer: A Single Center ExperienceAyşegül Sakin0mehmet naci aldemir1murat alay2Department of Internal Medicine, Van Research and Training Hospital, Van, TurkeyDepartment of Medical oncology, Yüzüncü yıl university, Van, TurkeyDepartment of Endocrinology and Metabolism, Yuzuncu Yil University, Van, Turkey.INTRODUCTION: In this retrospective study, we aimed to analyze the effect of choice of platinum chemotherapy (carboplatin vs. cisplatin) on survival in patients with small cell lung cancer(SCLC) and to identify the factors affecting survival. METHODS: A total of 87 metastatic SCLC patients with available data, who were equal to or greater than 18 years and were treated with platinum-based chemotherapy at first-line setting, were included. Patients were grouped according to type of platinum treatment as ‘cisplatin + etoposide(PE)' or ‘carboplatin + etoposide(CE)'. RESULTS: Of the 87 patients included in the study, 16 (%18,4) were female. The median age was 58 years. The numbers of patients treated with PE and CE were 65 and 22, respectively. The median progression-free survivals of patients treated with PE vs. CE were 6 months and 5 months, respectively (p=0.171), with corresponding overall survival (OS) durations of 9 months and 8 months (p=0.173). Performance status, administering thoracic radiotherapy and response to first-line chemotherapy were found to be the independent factors affecting OS. DISCUSSION AND CONCLUSION: In our study, first-line treatment with CE vs. PE did not affect survival in the patients with metastatic SCLC. However, the survival of patients with poor performance status was observed to be lower than those with better performance status. In addition, administering thoracic radiotherapy and a better response to first-line chemotherapy improved survival.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=vtd&un=VTD-46244small cell lung cancerprognostic factorscisplatincarboplatinsurvival |
| spellingShingle | Ayşegül Sakin mehmet naci aldemir murat alay The effect of choice of platinum on survival and factors affecting survival in metastatic small cell lung cancer: A Single Center Experience Van Tıp Dergisi small cell lung cancer prognostic factors cisplatin carboplatin survival |
| title | The effect of choice of platinum on survival and factors affecting survival in metastatic small cell lung cancer: A Single Center Experience |
| title_full | The effect of choice of platinum on survival and factors affecting survival in metastatic small cell lung cancer: A Single Center Experience |
| title_fullStr | The effect of choice of platinum on survival and factors affecting survival in metastatic small cell lung cancer: A Single Center Experience |
| title_full_unstemmed | The effect of choice of platinum on survival and factors affecting survival in metastatic small cell lung cancer: A Single Center Experience |
| title_short | The effect of choice of platinum on survival and factors affecting survival in metastatic small cell lung cancer: A Single Center Experience |
| title_sort | effect of choice of platinum on survival and factors affecting survival in metastatic small cell lung cancer a single center experience |
| topic | small cell lung cancer prognostic factors cisplatin carboplatin survival |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=vtd&un=VTD-46244 |
| work_keys_str_mv | AT aysegulsakin theeffectofchoiceofplatinumonsurvivalandfactorsaffectingsurvivalinmetastaticsmallcelllungcancerasinglecenterexperience AT mehmetnacialdemir theeffectofchoiceofplatinumonsurvivalandfactorsaffectingsurvivalinmetastaticsmallcelllungcancerasinglecenterexperience AT muratalay theeffectofchoiceofplatinumonsurvivalandfactorsaffectingsurvivalinmetastaticsmallcelllungcancerasinglecenterexperience AT aysegulsakin effectofchoiceofplatinumonsurvivalandfactorsaffectingsurvivalinmetastaticsmallcelllungcancerasinglecenterexperience AT mehmetnacialdemir effectofchoiceofplatinumonsurvivalandfactorsaffectingsurvivalinmetastaticsmallcelllungcancerasinglecenterexperience AT muratalay effectofchoiceofplatinumonsurvivalandfactorsaffectingsurvivalinmetastaticsmallcelllungcancerasinglecenterexperience |